NDAORALCAPSULE
Approved
Apr 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
FELDENE (piroxicam) by Pfizer is clinical pharmacology pharmacodynamics piroxicam capsules are a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. First approved in 1982.
Drug data last refreshed 8m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FELDENE (piroxicam) is an oral NSAID capsule that exhibits anti-inflammatory, analgesic, and antipyretic activities, likely through prostaglandin synthetase inhibition. It is used for management of rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. The drug's 50-hour half-life enables once-daily dosing with stable plasma concentrations and reaches steady state within 7–12 days.
$0.029BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D utilization, indicating a contracting team focused on managed decline rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Piroxicam capsules are a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of piroxicam, like that of other NSAIDs, is not completely understood but may…
Worked on FELDENE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.